Sofinnova: At the Intersection of Life Science, Finance & Innovation

Since our founding in 1976, Sofinnova has been active in life science investing and has primarily focused on therapeutic drugs over the last decade.  We are a healthcare investment firm with approximately $3.0B in assets under management and committed capital.* We invest in both private and public equity companies. 

Our Mission: to improve the lives of patients through science. We strive to provide outstanding results for those we serve: patients, entrepreneurs, and the investors that entrust us with their capital.

Historically Helping

We are long-term investors with an extensive track record of helping the world’s most transformative therapies come to fruition. From drug development and navigating the regulatory process to company building and IPO, we strive to be collaborative, meaningful board members, and excellent partners at every level.


Experience, Collaborative Team


Competitive Track Record


Deep Industry Knowledge

Exploring Possibilities

Sofinnova invests in late preclinical and clinical therapeutic companies across the U.S. and Europe. Key therapeutic areas include oncology, respiratory, dermatology, ophthalmology, neurology and women’s health. We actively partner with entrepreneurs in both the U.S. and Europe who want to rewrite the quality of healthcare today for a better life tomorrow.